Reliance Global Group, Inc. Q4 FY2025 earnings call

• Strategy built around two pillars: insurance and insure tech platform (recurring revenue, stable foundation) and Ezra International Group with Scale 51 model (identify innovative tech companies, build ownership positions). - Scale51 model identifies innovative tech companies, acquires ownership, supports growth into global markets, targeting sectors like cybersecurity, AI, fintech, digital health. - Rely Exchange technology-enabled distribution network saw personal lines, etc., premiums grow. - Monetized non-core operations like sale of Fortman Insurance Services, etc., to strengthen balance sheet and align with strategy. - Initial transactions under Scale 51 strategy: investment in InQuantum (post-quantum encryption) and agreement to acquire majority stake in Centec Medical (AI diagnostic with non-invasive breath analysis). - Transitioned NASDAQ ticker symbol from RELI to Ezra.

The insurance and insure tech platform generated more than $12 million in commission income in 2025. Personal lines, property, and casualty premiums generated through ReliExchange increased approximately 36% year over year, and policies written during the most recent health insurance open enrollment season increased approximately 72%. The balance sheet saw unrestricted cash increase $0.9 million to $1.3 million, welcome capital improve by $1.5 million to $1.9 million, and stockholders' equity increase $3.4 million to $6.4 million. Commission income for 2025 was $12.4 million compared to $14.1 million in 2024. Commission expense was $4.6 million compared to $4.2 million in 2024. Salaries and wages were $10.3 million in 2025 compared to $7.2 million in 2024. General and administrative expenses were $4.9 million compared to $4.2 million in 2024. Net loss improved to $7 million compared to $9.1 million in 2024. Adjusted EBITDA was a loss of $1.6 million compared to a loss of $0.3 million in 2024.

• Expect positive developments from Scale 51 strategy over next 6-12 months, with milestones to be achieved. - InQuantum could generate revenue even within the year. - Centec Medical's technology has potential for exciting financial rewards as it progresses.

• Forward-looking statements subject to risks, uncertainties, and assumptions as described in Form 10-K. Actual results could differ materially from forward-looking statements. - Risks related to the success of Scale 51 strategy, including development and commercialization of technologies by InQuantum and Centec Medical, and market acceptance of their products.

Q: Please share more about what investors should expect from the scale 51 strategy over the next six to 12 months?

A: Focus on companies somewhat already showing close to revenue, off to good start with InQuantum, milestones to be achieved for payments/investments, looking forward to more.

Q: Where is InQuantum currently in terms of product development and commercialization and timeline for revenue?

A: Excited revenue could be within the year, team working towards revenue, quantum computing is extremely fast, due diligence team impressed with InQuantum's team.

Q: Expand on what makes Centec's approach unique and differentiates it from other diagnostic technologies?

A: Centec focused on pancreatic cancer, biomarkers in human breath, early detection saves lives, due diligence team blown away, helps the world and the company financially